Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback